PCR-RFLP Detection of PAI-2 Variants in Myocardial Infarction

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 4, 2003, Pages 333-336

  Buyru, Nur ^a   Altinisik, Julide ^a   Gurel, Cigdem Bayram ^a   Ulutin, Turgut ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

MI; PAI 2; Polymorphism

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2;

ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROTEIN VARIANT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

EID: 0242523108     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900409     Document Type: Article

References (14)

1. Grant PJ, Prentice CLM. Coronary artery disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenhaw EGD, eds. Haemostasis and Thrombosis, vol. 2. Churchill Livingstone, Edinburgh and London, 1994:1231.
2. Dan K, Andreasen PA, Grondhal-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 1985;44:139.
3. Kruithof EKO, Vassali JK, Scleuning W-D, Mattaliano RJ, Bachmann P. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 1986;261:11207.
4. Schleef RR, Wagner NV, Loskutoff DJ. Detection of both type 1 and type 2 plasminogen activator inhibitor. J Cell Physiol 1988;134:269.
5. Webb AC, Collins KL, Snyder SE, Alexander SJ, Rosenwasser LJ, Eddy RL, Shows TB, Auron PE. Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment and homology to plasminogen activator-inhibitor. J Exp Med 1987;166:77.
6. Antolis TM, Clark MA, Barnes T, Lehrbach PR, Devine PL, Schevzov G, Goss NH, Stephens RW, Tolstoshev P. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc Natl Acad Sci USA 1988;85:985.
7. Kise U, Kaudewitz H, Henschen A, Astedt B, Kruithof EKO, Bachnann F. Determination of intermediates, products and cleavage sites in the reaction between plasminogen activator inhibitor type 2 and urokinase. FEBS Lett 1988;230:51.
8. Ye RD, Wun TC, Sadler JE. cDNA cloning and expression in Eschericia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987;262:3718.
9. Mikus P, Urano T, Lijeströ]m P, Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterization of the recombinant intracellular and extracellular forms. Eur J Biochem 1993;218:1071.
10. Kruithof EKO, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988;59:7.
11. Boekholdt SJ, Bijsterveld NR, Moons AHM, Levi M, Büller HR, Peters RJG. Genetic variation in coagulation and fibrinolytic proteins and their relation with acute myocardial infarction. Circulation 2001;104:3063.
12. Eriksson P, Kallin B, Van't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995;92:1851.
13. Ye S, Green FR, Scarabin PY, Nicaud V, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene associated with differences in plasma PAI-1 but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995;74:837.
14. Foy CA, Grant PS. PCR-RFLP detection of PAI-2 gene variants: Prevalence in ethnic groups and disease relationship in patients undergoing coronary angiography. Thromb Haemost 1997;77(5):955.